Figure 6.

klk1 and captopril also suppress interferon-stimulated genes. (A) Murine bone-marrow-derived dendritic cells (BMDCs) were stimulated with CpG-A for 2.5 h treated with antagonists for 30 min to block both B1 (DH—1 µg/ml) and B2 (H—10 µM) receptors and then stimulated with klk1 (1 µg/ml) or captopril (20 µM) for a further 4 h. Irf7 gene expression was analyzed by qPCR. Percent fold change was calculated by normalizing to CpG-A stimulation alone. (B) Human PBMCs were first treated with IFN-α for 3 h, 20 µM captopril was added and harvested after further 3 h and IRF7 and CXCL10 gene expression was analyzed by qPCR. Percent fold change was calculated by normalizing with IFN-α stimulation alone. Panels (A,B) represent average (mean + SEM) of at least three independent experiments, performed with independent BMDC cultures from each mouse or PBMCs from each donor; *p < 0.05, **p < 0.01, ***p < 0.001.